<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Moderna announces commitment to advance vaccines targeting 15 pathogens identified as biggest public health risk by WHO and CEPI into clinical studies by 2025 Moderna launches mRNA Access, a new collaborative enabling researchers around the world to utilize Moderna’s mRNA technology platform to pursue research in their own labs on emerging and neglected infectious diseases Moderna expands commitment to never enforce COVID-19 patents in the Gavi COVAX AMC for 92 low- and middle-income countries Moderna has entered into a Memorandum of Understanding with the Government of the Republic of Kenya to establish its first mRNA manufacturing facility on the continent of Africa CAMBRIDGE, MA / ACCESSWIRE / March 7, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its global public health strategy through four new initiatives aimed at advancing mRNA vaccines for the prevention of infectious diseases. First, Moderna is announcing a commitment to expand its global public health portfolio to 15 vaccine programs targeting priority pathogens[1] that threaten global health, advancing these vaccines into clinical studies by 2025.
...read full article on Accesswire
